Clinical Trials Directory
We are doing this study to learn if SAPIEN 3 valve system is safe and will work with adults and children who have a dysfunctional right ventricular outflow tract (RVOT) conduit or have an implanted valve in the pulmonic position.
Patients will first get Td preconditioning and a medicine called temozolomide for 5 days. On day 21, they will get the study vaccine, PEP-CMV. The first 3 vaccines will be given every 2 weeks. After that, the vaccines will be given once a month. The first treatment cycle lasts 77 days, and all cycles after that last 28 days. To join the study, patients must have lab and clinical tests done within 7 days before starting. Lab results must be no more than 7 days old when therapy begins. If therapy starts within 7 days of the lab tests, the tests do not need to be repeated.
People in this study will visit the research center two times each month to see the study doctor. The study can last up to 2 years. Treatment happens in cycles, and each cycle is 28 days long, which is about 4 weeks. A person can have up to 26 cycles, which equals about 2 years of treatment. The amount of medicine given will depend on the person’s weight, which is checked before each new cycle. The medicine is called tocilizumab. It blocks a protein called interleukin-6, which causes swelling in the body. This medicine is usually used for diseases where the immune system attacks the body, like arthritis, and it can also help with a problem called cytokine release syndrome after certain cancer treatments.
We are doing this study to learn how to best support young women making decisions about breast cancer surgery. We want to know what makes women feel uncertain about their decision-making so we can become better at providing the information they need. This study involves testing a web-based decision support tool that is designed to help young women with newly diagnosed breast cancer with their surgical decisions.
We are doing this study to find out if the use of continuous glucose monitors (CGMs) is worthwhile to help breast cancer patients and their providers monitor for hyperglycemia, or high blood sugar, during chemotherapy. A CGM is a small, wearable sensor that is attached to the skin to frequently measure your blood sugar level, and can share the measurements to your smartphone and to your medical team.
We are doing this study to find out if an experimental drug called Actinium-225 rosopatamab tetraxetan (the study drug) is a safe and effective option for patients with castration-resistant prostate cancer (CRPC).
We are doing this study to find out if an experimental drug called CRB-601 (the study drug) is a safe and effective option for people who have cancers with advanced solid tumors that did not improve with standard treatment.
This study lasts about 14 weeks and includes 8 planned visits to the clinic. If you qualify during the first part of the study, you will be randomly placed into one of three groups. Each person in the study will get two doses of a medicine called CRD-4730 and one dose that does not contain any medicine, called a placebo. The order of these doses is chosen by chance. Each dose is given over two weeks. You will go to the clinic on the first and last day of each dose. Between each dose, there is a two-week break when you do not take any medicine. During your visits, doctors may do check-ups like physical exams, blood and urine tests, heart tests, stress tests, and more. At home, you will use a device to check your heart every day and write down your results. You will also follow instructions for taking the medicine and keep a diary to record each time you take it.